WebMD
The amount of therapy combinations used to treat hormone receptor-positive (HR+) and HER2-negative metastatic breast cancer brings multiple options to the table for patients. Hadeel Assad, M.D., medical oncologist, co-leader of the Breast Cancer Multidisciplinary Team (MDT), member of the Phase I Clinical Trials MDT at Karmanos, outlined the therapy combinations, how oncologists determine what combinations to use and how genomic sequencing can assist with treatment decisions.
Read the article here.